Tags

Type your tag names separated by a space and hit enter

Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia.
Rev Rhum Engl Ed. 1995 Mar; 62(3):189-96.RR

Abstract

Hypercalcemia of malignancy is due either to local osteolysis at the site of bone metastases or to production by the malignancy of parathyroid hormone-related peptide, which shares some of the effects of parathyroid hormone. We used a radioimmunoassay (antiserum specific to the amino-terminus) to measure serum parathyroid hormone-related peptide levels in controls (n = 61), chronic renal failure patients (n = 10), patients with primary hyperparathyroidism (n = 19), cancer patients with (n = 35) or without (n = 57) hypercalcemia and/or bone metastases (n = 53 and n = 39, respectively), and patients with hematologic malignancies (n = 15). We set the upper limit of normal of the parathyroid hormone-related peptide assay at 2.7 pmol/L. The peptide was undetectable in two-thirds of healthy controls. Renal failure did not interfere with the assay. Eighteen of the 19 patients with primary hyperparathyroidism had normal levels. In contrast, 82% of patients with humoral hypercalcemia of malignancy (i.e., without detectable bone metastases) had increased levels; in this subgroup there was a significant inverse correlation between serum levels of the peptide and phosphorus. Elevation of parathyroid hormone-related peptide levels was less common among hypercalcemic patients with metastatic bone disease (38%). Four of the seven hypercalcemic patients with hematologic malignancies had elevated parathyroid hormone-related peptide levels. In our overall study population, serum calcium levels were weakly but significantly correlated with parathyroid hormone-related peptide levels. In conclusion, elevated parathyroid hormone-related peptide in a patient with hypercalcemia suggests a malignant disease.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Audran M
Department of Rheumatology, Angers Teaching Hospital, France.
Minebois-Villégas A
No affiliation info available
Lortholary A
No affiliation info available
Legrand E
No affiliation info available
Pascaretti C
No affiliation info available
Giraud P
No affiliation info available
Subra JF
No affiliation info available
Boasson M
No affiliation info available
Jallet P
No affiliation info available

MeSH

AdultAgedBone NeoplasmsCalciumFemaleHematologic DiseasesHumansHypercalcemiaHyperparathyroidismKidney Failure, ChronicMaleMiddle AgedNeoplasmsParathyroid HormoneParathyroid Hormone-Related ProteinProteinsRadioimmunoassayReference Values

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7788336

Citation

Audran, M, et al. "Contribution of Parathyroid Hormone-related Peptide to the Evaluation of Hypercalcemia." Revue Du Rhumatisme (English Ed.), vol. 62, no. 3, 1995, pp. 189-96.
Audran M, Minebois-Villégas A, Lortholary A, et al. Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia. Rev Rhum Engl Ed. 1995;62(3):189-96.
Audran, M., Minebois-Villégas, A., Lortholary, A., Legrand, E., Pascaretti, C., Giraud, P., Subra, J. F., Boasson, M., & Jallet, P. (1995). Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia. Revue Du Rhumatisme (English Ed.), 62(3), 189-96.
Audran M, et al. Contribution of Parathyroid Hormone-related Peptide to the Evaluation of Hypercalcemia. Rev Rhum Engl Ed. 1995;62(3):189-96. PubMed PMID: 7788336.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia. AU - Audran,M, AU - Minebois-Villégas,A, AU - Lortholary,A, AU - Legrand,E, AU - Pascaretti,C, AU - Giraud,P, AU - Subra,J F, AU - Boasson,M, AU - Jallet,P, PY - 1995/3/1/pubmed PY - 1995/3/1/medline PY - 1995/3/1/entrez SP - 189 EP - 96 JF - Revue du rhumatisme (English ed.) JO - Rev Rhum Engl Ed VL - 62 IS - 3 N2 - Hypercalcemia of malignancy is due either to local osteolysis at the site of bone metastases or to production by the malignancy of parathyroid hormone-related peptide, which shares some of the effects of parathyroid hormone. We used a radioimmunoassay (antiserum specific to the amino-terminus) to measure serum parathyroid hormone-related peptide levels in controls (n = 61), chronic renal failure patients (n = 10), patients with primary hyperparathyroidism (n = 19), cancer patients with (n = 35) or without (n = 57) hypercalcemia and/or bone metastases (n = 53 and n = 39, respectively), and patients with hematologic malignancies (n = 15). We set the upper limit of normal of the parathyroid hormone-related peptide assay at 2.7 pmol/L. The peptide was undetectable in two-thirds of healthy controls. Renal failure did not interfere with the assay. Eighteen of the 19 patients with primary hyperparathyroidism had normal levels. In contrast, 82% of patients with humoral hypercalcemia of malignancy (i.e., without detectable bone metastases) had increased levels; in this subgroup there was a significant inverse correlation between serum levels of the peptide and phosphorus. Elevation of parathyroid hormone-related peptide levels was less common among hypercalcemic patients with metastatic bone disease (38%). Four of the seven hypercalcemic patients with hematologic malignancies had elevated parathyroid hormone-related peptide levels. In our overall study population, serum calcium levels were weakly but significantly correlated with parathyroid hormone-related peptide levels. In conclusion, elevated parathyroid hormone-related peptide in a patient with hypercalcemia suggests a malignant disease.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 1169-8446 UR - https://www.unboundmedicine.com/medline/citation/7788336/Contribution_of_parathyroid_hormone_related_peptide_to_the_evaluation_of_hypercalcemia_ DB - PRIME DP - Unbound Medicine ER -